Frequency of New Onset Atrial Fibrillation in Patients Presenting with ST-Segment Elevation Myocardial Infarction DOI: https://doi.org/10.53350/pjmhs2023176112 Abstract Aim: To study the magnitude of atrial fibrillation in patients with ST segment elevation myocardial infarction. Methodology: Two hundred and thirty-six patients were selected through non-probability, consecutive sampling technique. Patients were divided into Group 1 who did not develop AF while group 2 included the new cases of A...
Jun 30, 2023•3 min
The prognostic value of myocardial salvage index by cardiac magnetic resonance in ST-segment elevation myocardial infarction patients: a systematic review and meta-analysis. 2023 Jun 16.doi: 10.1007/s00330-023-09739-1. Abstract Objective: To assess the prognostic value of myocardial salvage index (MSI) by cardiac magnetic resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) patients. Methods: We systematically searched PubMed, Embase, Web of Science, Cochrane Central, China Nati...
Jun 30, 2023•3 min
Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. 2023 Jun 4. doi: 10.1002/clc.24058. Abstract Purpose: To establish an association between beta-blockers (BBs), calcium channel blockers (CCBs), all-cause mortality, and hospitalization in patients with Heart failure with preserved Ejection Fraction (HFpEF). Methods: The ...
Jun 30, 2023•2 min
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial 2023 Jun 2;9(4):328-336. doi:10.1093/ehjcvp/pvad006. Abstract Aim: The aim of this study was to assess the effect of ticagrelor monotherapy among high-risk patients with anaemia undergoing percutaneous coronary intervention (PCI). Methods and results: In the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary In...
Jun 30, 2023•2 min
Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction https://doi.org/10.1016/j.amjcard.2023.04.022 Abstract Background: Beta blockers are uniformly recommended for all patients after myocardial infarction (MI), including those with diabetes mellitus (DM). This study assesses the impact of β-blocker type and dosing on survival in patients with DM after MI. Methods: A cohort of 6,682 patients in the Outcomes of Beta-blocker Therapy After Myocardial Infarction reg...
May 31, 2023•4 min
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction https://doi.org/10.1093/ehjcvp/pvad036 Abstract Background: Guideline recommendations for the treatment of heart failure with mildly reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of randomized trials. Objectives: We investigated predictors of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) and beta-blockers u...
May 31, 2023•3 min
Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction https://doi.org/10.1016/j.jacc.2023.03.388 Abstract Background: Spontaneous reperfusion , seen in ∼20% of patients with ST-segment elevation myocardial infarction (STEMI), manifests as normal epicardial flow in the infarct-related artery, with or without ST-segment resolution, before percutaneous coronary intervention (PCI). The drivers mediating this are unknown. Objective...
May 31, 2023•3 min
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials 2023 May;38(4):698-705. doi: 10.1177/02676591221076284. Abstract Objective: Ticagrelor may be an alternative to aspirin as it provides robust and consistent platelet inhibition. However, the effect of ticagrelor treatment in patients undergoing coronary artery bypass grafting (CABG) has not been well confirmed. We conducted a meta-analysis to appraise whether ticagrelor therapy aff...
May 31, 2023•3 min
Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials Cardiovasc Drugs Ther. 2023 Apr 1.doi: 10.1007 Background: Several clinical studies have produced diverse results regarding the efficacy and safety of early intravenous beta-blockers in patients with acute S...
May 02, 2023•4 min
Safe and Effective Early Use of Betablockers after Pediatric Heart Transplantation https://doi.org/10.1016/j.healun.2023.02.1366 Purpose: Beta-blockers (BBs) have been increasingly incorporated into the management of heart transplant recipients, with data supporting decreased mortality in adult recipients. However, very few studies have evaluated the use of BBs in pediatric recipients, and early use after pediatric heart transplantation (HTx) is still associated with hesitancy among providers. W...
May 02, 2023•3 min
Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction Am Heart J 2023 Apr; 258:17-26 doi: 10.1016 Background: The mechanisms underlying the increased risk of bleeding that female patients with ST-segment Elevation Myocardial Infarction (STEMI) exhibit, remains unclear. The present report assessed sex-related differences in response to pre-hospital dual antiplatelet therapy (DAPT) initiation in patients with ST...
May 02, 2023•3 min•Season 1Ep. 102
Ticagrelor Treatment is Associated With Increased Coronary Flow Reserve in Survivors of Myocardial Infarction https://doi.org/10.1016/j.hlc.2023.03.010 Abstract Background: The pleiotropic action of ticagrelor , with effects in addition to platelet inhibition, has been shown to improve endothelial function in patients with coronary artery disease . These positive effects are possibly adenosine mediated. This study investigated the association of ticagrelor therapy and coronary artery flow reserv...
May 02, 2023•3 min•Season 1Ep. 101
Sex-related bleeding risk in acute coronary syndrome patients receiving dual antiplatelet therapy with aspirin and a P2Y12 inhibitor Med Princ Pract. 2023 Mar 22. Abstract Aims To study sex differences in major bleeding in relation to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods and results The Collective Cardiology Research registry was designed to evaluate the application and outcomes of DAPT after ACS/PCI in the Rij...
Mar 30, 2023•2 min•Season 1Ep. 100
Effect of early metoprolol before PCI in ST-segment elevation myocardial infarction on infarct size and left ventricular ejection fraction. A systematic review and meta-analysis of clinical trials Clin Cardiol. 2022 Oct;45(10):1011-1028. Abstract Aim: This meta-analysis aims to look at the impact of early intravenous Metoprolol in ST-segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention (PCI) on infarct size, as measured by cardio magnetic resonance (CMR) and ...
Mar 30, 2023•2 min•Season 1Ep. 99
Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials Cardiovasc Ther. 2022 Dec 29;2022:8367444. Abstract Aim: Cardiotoxicity is a well-recognized complication of chemotherapy with Anthracyclines. However, results from trials evaluating beta-blockers for prevention are controversial. Therefore, we performed a meta-analysis to find whether prophylactic administration of beta-blockers can help prevent Anthracyclines-i...
Mar 30, 2023•2 min•Season 1Ep. 98
Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series Eur Heart J Case Rep. 2023 Feb 14;7(2):ytad051 Abstract Background: Essential thrombocythaemia (ET) is defined as a myeloproliferative neoplasm with a tendency to haemorrhage and thrombosis. Acute coronary thrombosis can be observed in 1 out of 10 patients. The management of ET patients with acute coronary syndrome (ACS) is a complex clinical condition that requires close follow-up. Case s...
Mar 30, 2023•2 min•Season 1Ep. 97
Interventional therapy of acute coronary syndromes in very old patient population and results of 2 years follow-up Egypt Heart J. 2023 Feb 22;75(1):14. doi: 10.1186/s43044-023-00340-x. Abstract Background: Research on cardiovascular treatment options and prognosis in very old age groups of patients is warranted. In our study, we evaluated and followed up on clinical conditions on admission and comorbidities of patients older than 80 years who were admitted to our hospital with acute myocardial i...
Mar 02, 2023•1 min•Season 1Ep. 96
Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trials J Clin Hypertens (Greenwich). 2023 Feb 8. doi: 10.1111/jch.14616. Online ahead of print. Abstract: The authors performed a meta-analysis to assess the efficacy of non-atenolol β-blockers as add-on to monotherapy or as a component of combination antihypertensive therapy in patients with hypertension. The authors searched and identified relevant randomized controlled tria...
Mar 02, 2023•2 min•Season 1Ep. 95
A predictive model of response to metoprolol in children and adolescents with postural tachycardia syndrome World J Pediatr. 2023 Feb 13. doi: 10.1007/s12519-022-00677-4. Online ahead of print. Abstract Background: The present work was designed to explore whether electrocardiogram (ECG) index-based models could predict the effectiveness of metoprolol therapy in pediatric patients with postural tachycardia syndrome (POTS). Methods: This study consisted of a training set and an external validation...
Mar 02, 2023•3 min•Season 1Ep. 94
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial Eur Heart J Cardiovasc Pharmacother. 2023 Jan 17;pvad006. Abstract Aim: The aim of this study was to assess the effect of ticagrelor monotherapy among high-risk patients with anemia undergoing percutaneous coronary intervention (PCI). Methods and results: In the TWILIGHT trial (Ticagrelor With Aspirin or Alone in High-Risk Patients after Co...
Mar 02, 2023•2 min•Season 1Ep. 93
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack Stroke. 2023 Feb 15. doi: 10.1161/STROKEAHA.122.041738. Abstract Background: It is unclear whether infarct location affects stroke recurrence after index ischemic stroke. We aimed to compare the risk of stroke recurrence and the responses to dual antiplatelets with ticagrelor-aspirin versus clopidogrel-aspirin between patients with posterior circulation infarct (PCI) and those w...
Mar 02, 2023•2 min•Season 1Ep. 92
Abstract Background: Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria have been used to identify high-risk patients undergoing percutaneous coronary intervention (PCI) in current clinical practice. This study aimed to evaluate the association between the number of ARC-HBR criteria and clinical outcomes in patients with acute coronary syndrome (ACS) after an emergent PCI. Methods: We assessed 338 consecutive patients with ACS who underwent successful emergent PCI between Jan...
Jan 31, 2023•2 min•Season 1Ep. 91
Abstract β-blockers have been widely utilized as a part of acute myocardial infarction (AMI) treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following myocardial infarction have a higher chance of surviving. Although many patients benefited from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction, chronic pulmonary disease, and elderly people. In individuals with post-acute coronary syndrome and normal l...
Jan 31, 2023•1 min•Season 1Ep. 90
Abstract Objective: To determine if the baseline baroreflex sensitivity (BRS) could be a useful predictor for the metoprolol therapeutic efficacy on postural orthostatic tachycardia syndrome (POTS) in children. Methods: In this retrospective case-control study, 54 children suffering from POTS treated with metoprolol were recruited from the pediatric department of Peking University First Hospital. After 2-3 months of metoprolol treatment, all subjects were divided into responders and non-responde...
Jan 31, 2023•2 min•Season 1Ep. 89
Abstract Background: No study has compared pharmacologic properties of ticagrelor and clopidogrel in non-dialysis patients with stage 4-5 chronic kidney disease (CKD). Methods: We conducted a double-blind RCT to compare effects of ticagrelor and clopidogrel in 48 CKD, with the primary outcome of ADP-induced platelet aggregation (WBPA) after 2 weeks of DAPT. In a parallel arm, we compared effects of 2 weeks of ticagrelor plus aspirin on mean changes in WBPA and markers of thromboinflammation amon...
Jan 31, 2023•2 min•Season 1Ep. 88
The prognostic effect of ST-elevation in lead aVR on coronary artery disease, and outcome in acute coronary syndrome patients: a systematic review and meta-analysis Eur J Med Res. 2022 Dec 21;27(1):302. Abstract Background: Rapid diagnosis of coronary artery disease has an important role in saving patients. The aim of this study is to evaluate if aVR lead ST-elevation (STE) can predict LM/3VD, left main (LM) disease, and three-vessel disease (3VD), outcome in acute coronary syndrome (ACS) patien...
Dec 26, 2022•2 min•Season 1Ep. 87
Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis PLoS One. 2022 Dec 19;17(12):e0279171. Abstract Background: Trials in patients receiving dialysis have demonstrated that β-blockers reduce all-cause mortality and cardiovascular events. However, differences still exist within-class comparative effectiveness studies of the therapeutic benefits of β-blockers in dialysis patients. Objective: ...
Dec 26, 2022•2 min•Season 1Ep. 86
Efficacy of metoprolol plus atorvastatin for carotid atherosclerosis and its influence on carotid intima-media thickness and homocysteine level Abstract Objective: To analyze the effects of metoprolol (MET) plus atorvastatin (ATO) on carotid intima-media thickness (IMT) and homocysteine (Hcy) level in carotid atherosclerosis (CAS) patients. Methods: In this retrospective study, 90 patients with CAS admitted to the Hangzhou Ninth People's Hospital between January 2019 and July 2021 were enrolled,...
Dec 26, 2022•2 min•Season 1Ep. 85
Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis Abstract: Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of coronary artery disease (CAD). In patients with acute coronary syndrome (ACS), guidelines recommend a potent P2Y12 inhibitor in addition to aspirin. For those with complicated and advanced CAD requiring complex percutaneous...
Dec 26, 2022•3 min•Season 1Ep. 84
Abstract Background: This study aimed to investigate associations of serum high-sensitivity C-reactive protein (hsCRP) and social support (SS) levels with suicidal ideation (SI), and to evaluate potential modifying effects of SS on the associations between serum hsCRP levels and SI in two longitudinal cohorts with cardio-/cerebrovascular diseases. Methods: 1152 acute coronary syndrome (ACS) and 423 stroke patients were recruited at baseline within 2 weeks of disease onset, and evaluated for: i) ...
Dec 03, 2022•3 min•Season 1Ep. 83
